NewslettersHematopoiesis NewsKite’s CAR T-Cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)By mladbrook - July 26, 20220284Kite announced that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus® for the treatment of adult patients 26 years of age and above with r/r ALL.[Gilead Sciences, Inc.]Press Release